The global neovaginal surgery market size was valued at USD 1.09 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 3.63% from 2020 to 2027. Neovaginal surgery includes the creation of a vagina and is opted for by transgender individuals along with women with vaginal agenesis. Factors, such as an increase in the number of gender confirmation surgeries and availability of insurance, are expected to drive the market growth over the forecast period. In recent years, there has been an increase in access to gender confirmation procedures and social acceptance of transgender individuals. According to the American Society of Plastic Surgeons (ASPS), the number of gender confirmation surgeries increased by 15% from 2018 to 2019 in the U.S.
Insurance companies from many regions are providing health coverage for Sex Reassignment Surgery (SRS). For instance, the HIF - Health Insurance Fund of Australia includes insurance coverage for SRS, such as neovaginal surgery. Developing countries, such as India, are also providing financial assistance to individuals seeking such surgeries. Owing to the increasing demand, service providers are taking initiatives to increase their geographic reach to cater to increased patient inflow.
For instance, in June 2018, Cedars-Sinai expanded its transgender services to provide care in Culver City and Beverly Hills. Innovations in surgical techniques are contributing to improving the patient experience by reducing the required time and cost for the surgery. The Covid-19 pandemic has posed challenges for the healthcare service providers and to patients seeking care for various health conditions.
Thus, many hospitals have canceled or postponed elective procedures, such as gender-affirming surgeries, to save resources. This may hamper the market growth to some extent. For instance, the GRS Montreal, Inc. canceled the gender reassignment surgeries from March 18, 2020, to June 1, 2020. This temporary cancellation is accompanied by a patient’s fear of having to go through the preauthorization process again.
Sex reassignment surgery was the dominant treatment type segment of the global market in 2019. The segment accounted for the largest revenue share of more than 55% in the same year and is estimated to expand further at the fastest CAGR from 2020 to 2027. This growth is attributed to the rising demand for such surgeries, particularly Male-to-Female (MtF) surgeries, across the globe. Based on the treatment type, the market is segmented into vaginal agenesis treatment, vaginal atresia treatment, and SRS.
The various factors, such as reimbursement and increasing demand, are contributing to the segment growth. Medicare did not include cosmetic surgery and surgeries for gender change in the past. However, in 2014, increasing demand for these surgeries led to the inclusion of gender reassignment surgeries in the reimbursement policy. Insurance providers from many regions are including SRS in their health cover.
For instance, the HIF - Health Insurance Fund of Australia, the Australian not-for-profit health fund, includes insurance coverage for SRS, such as neovaginal surgery. Vaginal agenesis is a rare birth defect with an incidence of 1 in 5,000 women. Various surgical methods, such as sigmoid vaginoplasty and Davydov procedure, are adopted for neovagina creation in agenesis patients. Sigmoid vaginoplasty is efficient in a low resource medical facility.
In terms of revenue, the laparoscopic neovaginal surgeries kits segment accounted for the largest market share of over 50% in 2019. The segment will grow further at the fastest CAGR from 2020 to 2027 due to the rising number of laparoscopic procedures performed globally as a result of increasing preference for minimally invasive surgeries for treating vaginal agenesis in female patients.
Based on products, the market is segmented into vaginal dilators, vaginal stents, and laparoscopic neovaginal surgeries kits. Vaginal dilators are designed to restore or expand the tissues and musculature of the vaginal opening. Increasing adoption of vaginal dilators for neovaginal construction is anticipated to boost the segment growth. Moreover, the adoption of silicone dilators among women with Mayer–Rokitansky–Küster–Hauser syndrome (MRKH) is increasing.
The growing number of laparoscopic procedures performed globally owing to increasing preference for minimally invasive surgeries for treating vaginal agenesis is driving laparoscopic neovaginal surgeries kits segment growth. In addition, growing consumer preference for laparoscopic procedures for vaginal reconstruction owing to various disadvantages of traditional operative techniques (skin grafting or intestinal substitution), which includes intestinal obstruction, excess mucous production, adenocarcinoma, prolapse, colitis, prolonged recovery time, and significant scarring of the neovagina, is boosting demand for laparoscopic neovaginal surgery kits.
Europe dominated the neovaginal surgery market by product in 2019 and accounted for a share of over 37% due to factors, such as increased demand for vaginoplasty, presence of regulations for these treatments, and initiatives to spread awareness regarding cosmetic surgery and associated safety concerns.
With rising social awareness and growing acceptance of gender reassignment in the majority of the European countries, the number of surgical procedures and techniques is rapidly increasing, thereby driving the demand for products including vaginal stents, dilators, and laparoscopic neovaginal surgery kits used to perform these procedures. However, the Asia Pacific region is expected to register the fastest growth rate over the forecast period.
Major factors contributing to this growth are increasing awareness regarding neovaginal surgery and the rising number of medical tourists in the region due to low healthcare costs. The market in North America is well-regulated for cosmetic treatments. Easy availability of insurance coverage and an increasing number of manufacturers and medical practitioners that treat vaginal anomalies are the key factors contributing to the region’s growth.
Product manufacturers are majorly located in North America and Europe. Key manufacturers are adopting various expansion strategies to enhance their market presence. For instance, in March 2017, Owen Mumford Ltd. inaugurated its new facility in Malaysia, which will enable the expansion of its business in Asia Pacific. Some of the key players in the global neovaginal surgery market are:
Vuvatech
Owen Mumford Ltd.
KESSEL medintim GmbH
Phuket Plastic Surgery Institute (PPSI)
Chettawut Plastic Surgery Center
González-Fontana
Icahn School of Medicine at Mount Sinai
Report Attribute |
Details |
Market size value in 2020 |
USD 1.11 billion |
Revenue forecast in 2027 |
USD 1.42 billion |
Growth Rate |
CAGR of 3.63% from 2020 to 2027 |
Base year for estimation |
2019 |
Historical data |
2016 - 2018 |
Forecast period |
2020 - 2027 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2020 to 2027 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Treatment type, product, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Thailand; Indonesia; Brazil; Mexico; Argentina; South Africa |
Key companies profiled |
Vuvatech; Owen Mumford Ltd.; KESSEL medintim GmbH; Phuket Plastic Surgery Institute (PPSI); Chettawut Plastic Surgery Center; González-Fontana; Icahn School of Medicine at Mount Sinai |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global neovaginal surgery market report on the basis of treatment type, product, and region:
Treatment Type Outlook (Revenue, USD Million, 2016 - 2027)
Vaginal Agenesis Treatment
Vaginal Atresia Treatment
McIndoe Technique
Vecchietti Technique
Sex Reassignment Surgery
Product Outlook (Revenue, USD Million, 2016 - 2027)
Vaginal Dilators
Vaginal Stents
Laparoscopic Neovaginal Surgeries Kits
Regional Outlook (Revenue, USD Million, 2016 - 2027)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
Thailand
Indonesia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
b. The global neovaginal surgery market size was estimated at USD 1.09 billion in 2019 and is expected to reach USD 1.11 billion in 2027.
b. The global neovaginal surgery market is expected to grow at a compound annual growth rate of 3.63% from 2020 to 2027 to reach USD 1.42 billion by 2027.
b. Europe dominated the neovaginal surgery market with a maximum share in 2019 due to factors such as an increase in demand for vaginoplasty and increasing awareness regarding safety concerns associated with cosmetic surgery.
b. Some of the key players in the neovaginal surgery market are Vuvatech, Owen Mumford Ltd., KESSEL medintim GmbH, Phuket Plastic Surgery Institute (PPSI), Chettawut Plastic Surgery Center, González-Fontana, and Icahn School of Medicine at Mount Sinai.
b. Key factors driving the neovaginal surgery market are increasing awareness regarding the availability of sex reassignment surgery and availability of insurance for the treatment.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.